Clinical Trials Directory

Trials / Unknown

UnknownNCT05666492

"Platelet Rich Plasma for the Management of Post-Viral Olfactory Dysfunction.

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
120 (estimated)
Sponsor
Thomas Jefferson University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

SARS COV-19 has resulted in prolonged olfactory dysfunction in many patients. The investigators aim to compare the effect of topical platelet-rich plasma (test) vs saline (placebo) in patients with covid-related post-viral olfactory dysfunction.

Detailed description

The investigators hypothesize that the use of topical PRP will improve smell identification, threshold, and smell-related quality of life in comparison to a placebo. This study will provide critical information for a promising new treatment of olfactory dysfunction with the highest level of evidence, in a randomized, placebo-controlled trial. Preliminary results from an ongoing pilot study investigating topical PRP is the basis for the hypothesis. By investigating the efficacy of topical PRP in smell restoration, the investigators will provide a less-invasive way to deliver this autologous product. A randomized trial will set a precedent for the use of this treatment to serve a growing population of patients affected with post-COVID olfactory dysfunction. Over a period of one year, participants with post-viral olfactory dysfunction will be randomly assigned to a test or control group and will visit the clinic monthly for three months to receive PRP or saline based on their randomized group. This will be followed by 9 months of at-home electronic visits. At each visit both the test and control groups will undergo smell testing and will fill quality of life questionnaire.

Conditions

Interventions

TypeNameDescription
OTHERPlatelet rich plasmaPlatelet-rich plasma will be placed on the olfactory epithelium topically.
OTHERSalineSaline will be placed on the olfactory epithelium topically.

Timeline

Start date
2022-08-17
Primary completion
2024-08-17
Completion
2024-08-17
First posted
2022-12-27
Last updated
2022-12-27

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05666492. Inclusion in this directory is not an endorsement.